Sigurdardottir S L, Freysdottir J, Vikingsdottir T, Valdimarsson H, Vikingsson A
Department of Immunology, Landspitali University Hospital, Reykjavik, Iceland.
Scand J Rheumatol. 2008 Nov-Dec;37(6):469-76. doi: 10.1080/03009740802225876.
The effects of non-steroidal anti-inflammatory drugs (NSAIDs) on acute inflammation have been thoroughly investigated. NSAIDs are, however, also prescribed for patients with chronic inflammation, such as rheumatoid arthritis (RA), and objective improvement suggestive of anti-inflammatory action from NSAIDs has not been convincingly shown in chronic RA. An antigen-induced arthritis (AIA) model was used to investigate the effects of piroxicam on chronic inflammation.
AIA was induced by injecting methylated bovine serum albumin (mBSA) into the knee joints of previously immunized rats that were treated orally with the NSAID piroxicam or with saline. This treatment was started either before AIA was induced or after it had reached a chronic phase. The findings were recorded by clinical and histological assessment of the joints.
The piroxicam group developed significantly less acute and subsequent chronic knee joint inflammation but this was only evident if the drug was administered prior to the intra-articular mBSA injections. Piroxicam treatment that was initiated during the chronic inflammation did not have any clinical effect, whereas short-term corticosteroid treatment abolished the chronic inflammation. Moreover, histological analysis of the chronic inflammation revealed significantly more inflammatory changes in the piroxicam group compared with the control group.
Piroxicam treatment had no beneficial effects on the chronic stable inflammation in this model and might even delay histological resolution. As the anti-inflammatory effect of piroxicam is restricted to acute inflammation, the use of NSAIDs during periods of chronic stable arthritis in humans, such as in RA, may need to be investigated.
非甾体抗炎药(NSAIDs)对急性炎症的影响已得到充分研究。然而,NSAIDs也被用于治疗慢性炎症患者,如类风湿关节炎(RA),但在慢性RA中,尚未有令人信服的证据表明NSAIDs具有抗炎作用并能带来客观改善。本研究使用抗原诱导性关节炎(AIA)模型来探究吡罗昔康对慢性炎症的影响。
通过向先前免疫的大鼠膝关节内注射甲基化牛血清白蛋白(mBSA)诱导AIA,这些大鼠口服NSAID吡罗昔康或生理盐水。该治疗在AIA诱导前或进入慢性期后开始。通过对关节的临床和组织学评估记录结果。
吡罗昔康组急性和随后的慢性膝关节炎症明显减轻,但仅在关节内注射mBSA前给药时才明显。在慢性炎症期间开始的吡罗昔康治疗没有任何临床效果,而短期皮质类固醇治疗可消除慢性炎症。此外,对慢性炎症的组织学分析显示,与对照组相比,吡罗昔康组的炎症变化明显更多。
在该模型中,吡罗昔康治疗对慢性稳定炎症没有有益作用,甚至可能延迟组织学消退。由于吡罗昔康的抗炎作用仅限于急性炎症,因此可能需要研究在人类慢性稳定关节炎期间(如RA)使用NSAIDs的情况。